Richard C. Mulligan, PhD

HSCI Alumni: Richard C. Mulligan, PhD

Harvard Medical School
Richard C. Mulligan, PhD

The Mulligan laboratory continues to be interested in the development of methods for the introduction of genes into mammalian cells, and the application of those methods in a numbers of areas of biology and medicine. Over the past few years, the laboratory has had a particular focus on the physical and phenotypic characterization of bone-marrow and organ-derived stem cell populations and the genetic modification of those cells, and the development of safer methods for gene therapy. Efforts in the area of vector safety have included the development of improved methods for the transduction of purified hematopoietic stem cells, the development of novel technologies for the control of vector gene expression in mammalian cells, and the development of new systems for the conditional ablation of transduced cells (eg suicide markers).


Richard C. Mulligan is the Mallinckrodt Professor of Genetics at Harvard Medical School, and Director of the Harvard Gene Therapy Initiative, an integrated effort amongst basic science and clinical investigators at Harvard University and its Affiliated Hospitals directed towards the pre-clinical and clinical evaluation of novel gene-based therapies for inherited and acquired diseases. Professor Mulligan received his B.S. degree from Massachusetts Institute of Technology, and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine, where he studied under Professor Paul Berg. After receiving postdoctoral training at the Center for Cancer Research at MIT with Professors David Baltimore and Phillip Sharp, Professor Mulligan joined the MIT faculty and subsequently was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Children's Hospital and Harvard in 1996. His honors include the MacArthur Foundation Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize.

Professor Mulligan is an internationally recognized pioneer in the development of new technologies for transferring genes into mammalian cells. Scientists use the specialized tools created in his laboratory to unravel basic questions about human development and to devise new therapies for the treatment of both inherited diseases and acquired diseases.



HSCI Status